Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.

@article{Visser2004Rizatriptan5M,
  title={Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.},
  author={W. Hester Visser and Paul K Winner and Kim M Strohmaier and Meghan Klipfel and Yahong Peng and Kathleen A. Mccarroll and Roger Cady and Donald E. Lewis and Robert McC. Nett},
  journal={Headache},
  year={2004},
  volume={44 9},
  pages={891-9}
}
OBJECTIVE To examine the short- and long-term efficacy and tolerability of rizatriptan 5 mg in adolescents with migraine. METHODS Two studies were conducted in patients aged 12 to 17 years. The first study was a randomized, double-blind, placebo-controlled, single-attack study followed by a randomized, 1-year, open-label extension. The second study was a randomized, 1-year, open-label study. In the single-attack study, patients treated a moderate or severe migraine headache and up to two… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…